MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:36Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Angiotensin receptor blockers]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #184

2026-05-23T03:56:08Z

parser-claude batch MedTemplate pre-fill, Top 300 #184

New page

{{MedTemplate
| generic = Telmisartan
| brand = Micardis
| structure =
| classes = [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="hypertension-use">Hypertension</vote>, <vote slug="cv-risk-reduction-arb-use">Cardiovascular risk reduction in selected high-risk patients (ONTARGET-derived label)</vote>
| starting_dose = 40 mg PO once daily; titrate to 80 mg
| preparations = 20, 40, 80 mg tablets
| fda_max = 80 mg/d
| pill_id =
| routes = Oral
| onset = BP effect within 1-2 weeks
| duration = 24 hours
| halflife = ~24 hours (longest of the ARB class; suits patients with morning BP surge)<ref name="micardis-label">FDA Prescribing Information, Micardis (telmisartan), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020850s039lbl.pdf</ref>
| bioavailability = 42-58% (oral; dose-dependent)<ref name="micardis-label" />
| pregnancy = '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection<ref name="micardis-label" />
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="telmisartan-mech-claim">Telmisartan is a selective AT1 angiotensin-II receptor antagonist with partial PPAR-γ agonism at therapeutic concentrations; the latter contributes to favorable metabolic effects (lipid handling, glucose tolerance) that distinguish it modestly within the ARB class.</vote> The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence<ref name="micardis-label" />.
}}

== References ==
<references />

Telmisartan - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #184